^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pegylated liposomal doxorubicin

    i
    Other names: Doxorubicin Hydrochloride Cytori, ATI-0918, Dox-SL, SPI 49, JNS-002, TLC177, TLC 177
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    1d
    Association of Pegylated Liposomal Doxorubicin with Improved Overall Survival Compared with Epirubicin in Early-Stage Breast Cancer: A Population Based Study from Taiwan. (PubMed, Breast Cancer (Dove Med Press))
    In this nationwide propensity score-matched cohort, adjuvant Lipo-Dox was associated with sustained overall survival benefits without increased cardiotoxic risk compared with epirubicin. Lipo-Dox may represent a favorable anthracycline alternative, particularly for patients with cardiovascular comorbidities or elevated cardiotoxicity risk.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    pegylated liposomal doxorubicin • epirubicin
    1d
    Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=182, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Irene (pyrotinib) • cyclophosphamide • pegylated liposomal doxorubicin
    7d
    Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report. (PubMed, Front Oncol)
    Given the advanced stage, the patient received a systemic combination of tislelizumab, cyclophosphamide, pegylated liposomal doxorubicin, and nedaplatin, initially combined with local intrapleural therapy. This case highlights a diagnostic pitfall in lung tumors exhibiting squamoid immunophenotypes and underscores the necessity of incorporating myoepithelial markers into the diagnostic workup. Furthermore, it provides a cautiously interpreted clinical observation of immune checkpoint inhibitor-based combination therapy in advanced PACC.
    Journal • Pleural effusion • PD(L)-1 Biomarker • IO biomarker
    |
    SOX10 (SRY-Box 10) • TP63 (Tumor protein 63)
    |
    Tevimbra (tislelizumab-jsgr) • cyclophosphamide • pegylated liposomal doxorubicin • Aqupla (nedaplatin)
    12d
    A pH-sensitive nanococktail enabled cancer stem cell elimination, deep tumour penetration, and tumour shrinkage. (PubMed, Int J Pharm)
    This study investigated the potential of a fusogenic pH-sensitive liposomal (pSL) nanococktail comprising doxorubicin and bufalin for targeting CSCs in clinically relevant HER2-positive breast cancer models, including cell lines (CD44high HCC1954 and CD44low BT474), homotypic and heterotypic spheroids, patient-derived organoids, and orthotopic HCC1954 mouse xenografts. In vivo, the pSL-cocktail was well-tolerated and achieved significant tumour shrinkage, whereas DOXIL-like liposomes and free drugs showed minimal activity or severe adverse effects. Overall, this pSL-cocktail demonstrates strong potential for CSC-elimination and tumour clearance through synergistic drug combination, superior tumour penetration, and endosomal pH-triggered intracellular drug release.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    doxorubicin hydrochloride • pegylated liposomal doxorubicin
    15d
    RAPID: The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Fudan University | Trial primary completion date: Aug 2024 --> Aug 2027
    Trial primary completion date
    |
    Tyvyt (sintilimab) • pegylated liposomal doxorubicin
    19d
    RAINFOL-02: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China (clinicaltrials.gov)
    P3, N=82, Not yet recruiting, Genmab
    New P3 trial • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)
    28d
    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)
    P1/2, N=460, Recruiting, Merck Sharp & Dohme LLC | N=280 --> 460
    Enrollment change
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)
    28d
    ETCTN 10563: Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (clinicaltrials.gov)
    P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • peposertib (M3814) • Duomeisu (pegylated liposomal doxorubicin)
    1m
    Severe anemia as a risk factor in Japanese patients with ovarian cancer receiving olaparib: a retrospective study. (PubMed, BMC Cancer)
    Prior PLD therapy, impaired renal function, and pre-existing anemia substantially increased the risk of severe anemia during olaparib treatment. These findings highlight the need for risk-adaptive monitoring strategies and proactive management in patients with high risk for severe anemia. Further studies with larger cohorts of patients with renal impairment are recommended to support dose-adjustment strategies and optimize treatment safety.
    Retrospective data • Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Lynparza (olaparib) • pegylated liposomal doxorubicin
    1m
    PROTA: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum resistant
    |
    Keytruda (pembrolizumab) • pegylated liposomal doxorubicin • igrelimogene litadenorepvec (TILT-123)
    1m
    Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, National Taiwan University Hospital
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • cyclophosphamide • pegylated liposomal doxorubicin
    1m
    NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2/3, N=444, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Apr 2027
    Trial completion date • Platinum resistant
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)